Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ. 1, BQ. 1.1., and XBB. 1.5 predominant omicron variants in three US health systems: a …
NR Aggarwal, LE Beaty, TD Bennett… - The Lancet Regional …, 2024 - thelancet.com
Summary Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19 …
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19 …
Effectiveness of molnupiravir and nirmatrelvir–ritonavir in hospitalized patients with COVID-19: a target trial emulation study
Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …
Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
C Weil, T Bergroth, A Eisenberg, YO Whiteside… - Epidemiologia, 2023 - mdpi.com
Molnupiravir (MOV) was introduced in Israel in January 2022 during the SARS-CoV-2
Omicron surge for high-risk patients contraindicated for nirmatrelvir/ritonavir. This …
Omicron surge for high-risk patients contraindicated for nirmatrelvir/ritonavir. This …
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA. 4 and BA. 5 in Colorado, USA: a retrospective …
NR Aggarwal, KC Molina, LE Beaty… - The Lancet Infectious …, 2023 - thelancet.com
Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression
AA Butt, P Yan, OS Shaikh - Plos one, 2024 - journals.plos.org
Background In randomized controlled trials, Nirmatrelvir/ritonavir (NMV/r) and Molnupiravir
(MPV) reduced the risk of severe/fatal COVID-19 disease. Real-world data are limited …
(MPV) reduced the risk of severe/fatal COVID-19 disease. Real-world data are limited …
Molnupiravir use and 30-day hospitalizations or death in a previously uninfected nonhospitalized high-risk population with COVID-19
Background Clinical benefit of molnupiravir (MPV) in coronavirus disease 2019 (COVID-19)–
infected subpopulations is unclear. Methods We used a matched cohort study design to …
infected subpopulations is unclear. Methods We used a matched cohort study design to …
Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among US veterans: target trial emulation studies with one-month and six-month …
KL Bajema, K Berry, E Streja, N Rajeevan… - Annals of internal …, 2023 - acpjournals.org
Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
The impact of nirmatrelvir-ritonavir in reducing hospitalizations among high-risk patients with SARS-CoV-2 during the omicron predominant era
MM Al-Obaidi, AB Gungor, S Murugapandian… - The American Journal of …, 2023 - Elsevier
Background The coronavirus disease 2019 (COVID-19) pandemic has caused significant
morbidity and mortality in high-risk populations. Several therapeutics have been developed …
morbidity and mortality in high-risk populations. Several therapeutics have been developed …
Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients
K Cowman, A Miller, Y Guo, MH Chang… - Journal of …, 2023 - academic.oup.com
Objectives To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …
Early access to oral antivirals in high-risk outpatients: good weapons to fight COVID-19
G Bruno, M Giotta, S Perelli, G De Vita, N Bartolomeo… - Viruses, 2022 - mdpi.com
Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe
Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data …
Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data …